Citi says Arkema is best placed to gain from chemicals recovery in 2025
** Citigroup says Europe's diversified chemicals are "under-earning, under-owned, and trade on cheap valuations", which limits their downside despite global uncertainties over demand and tariffs
** "Current demand trends seem insufficient to drive upgrades while the Trump election win has cast further doubts on the outlook" - Citi
** However, the sector could see volume recovery in 2025 driven by expected upturns in European agriculture and construction, it says
** It upgrades Arkema AKE.PA to "buy" from "neutral" with 7% higher PT of EUR 100, vs Tuesday's closing price of EUR 74.05
** Citi says Arkema is best positioned for 2025, backed by its low macro-dependency compared to peers, high volume recovery potential and its strong U.S. market exposure
** Out of 18 analysts that cover Arkema, 15 rate the stock "strong buy" or "buy" and three "hold" - LSEG
** Citi maintains "buy" on Clariant CLN.S, Evonik EVKn.DE and Wacker WCHG.DE, and opens a pair trade of Arkema and Syesqo ("neutral") SYENS.BR with a relative preference for the former
Reporting by Jakob Van Calster
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
